Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase
View Patent ↗In one aspect, the invention relates to substituted N-phenylpyrimidin-2-amine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of Axl kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the Axl kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound having the following structure (I):
wherein L 1 is selected from O and NR 5 , wherein n is 0 or 1;
wherein R 5 is selected from hydrogen and C1-C6 alkyl;
wherein L 2 is selected from CH 2 and NCH 3 , provided that L 2 is CH 2 when Y is N;
wherein Y is selected from CH or N;
wherein Z is selected from NR 6 and CH 2 ;
wherein R 6 is selected from hydrogen and CH 3 ;
wherein each of R 1a and R 1b is independently selected from hydrogen, halogen, OH, CN, SO 2 CH 3 , C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 polyhaloalkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 cyanoalky, and NH(C═O)R 7 ;
wherein R 7 is selected from hydrogen and C1-C6 alkyl;
wherein R 2 is selected from hydrogen, C1-C6 alkyl, SO 2 R 8 and C═OR 8 ;
wherein R 8 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and NR 10 R 11 ;
wherein R 10 is selected from hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl; and wherein R 11 , when present, is selected from hydrogen and C1-C6 alkyl; or R 10 and R 11 are covalently bonded and, together with the intermediate nitrogen, comprise an optionally substituted 3-7 membered heterocycloalkyl ring:
wherein R 3 is a fluoro; and
wherein R 4 is selected from hydrogen, halogen, Ar 1 , C1-C6 alkyl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl;
wherein Ar 1 is either phenyl substituted with 0-3 substituents independently selected from cyano, C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino or is monocyclic heteroaryl substituted with 0-3 substituents independently selected from halo, cyano, C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino;
wherein R 12 is selected from C1-C6 alkyl and C3-C6 cycloalkyl;
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof.
2. The compound of claim 1 , wherein R 1b is selected from hydrogen and halogen.
3. The compound of claim 1 , wherein R 4 is hydrogen.
4. The compound of claim 1 , wherein the compound is selected from:
5. A method for the treatment of cancers of the lung or pancreas in a mammal, wherein the cancer of the lung or pancreas is associated with AXL receptor kinase dysfunction, wherein the method comprises the step of administering to the mammal an effective amount of at least one compound having the following structure (I):
wherein L 1 is selected from O and NR 5 , wherein n is 0 or 1;
wherein R 5 is selected from hydrogen and C1-C6 alkyl;
wherein L 2 is selected from CH 2 and NCH 3 , provided that L 2 is CH 2 when Y is N;
wherein Y is selected from CH or N;
wherein Z is selected from NR 6 and CH 2 ;
wherein R 6 is selected from hydrogen and CH 3 ;
wherein each of R 1a and R 1b is independently selected from hydrogen, halogen, OH, CN, SO 2 CH 3 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 polyhaloalkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 cyanoalky, and NH(C═O)R 7 ;
wherein R 7 is selected from hydrogen and C1-C6 alkyl;
wherein R 2 is selected from hydrogen, C1-C6 alkyl, SO 2 R 8 and C═OR 8 ;
wherein R 8 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and NR 10 R 11 ;
wherein R 10 is selected from hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl; and wherein R 11 , when present, is selected from hydrogen and C1-C6 alkyl; or R 10 and R 11 are covalently bonded and, together with the intermediate nitrogen, comprise an optionally substituted 3-7 membered heterocycloalkyl ring:
wherein R 3 is a halogen; and
wherein R 4 is selected from hydrogen, halogen, Ar 1 , C1-C6 alkyl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl;
wherein Ar 1 is either phenyl substituted with 0-3 substituents independently selected from cyano, C1-C6 alkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino or is monocyclic heteroaryl substituted with 0-3 substituents independently selected from halo, cyano, C1-C6 alkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino;
wherein R 12 is selected from C1-C6 alkyl and C3-C6 cycloalkyl;
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof.
6. The method of claim 5 , further comprising the step of identifying a mammal in need of treatment of a cancer of the lung or pancreas.
7. The method of claim 5 , wherein the mammal has been diagnosed with a cancer of the lung or pancreas prior to the administering step.
8. The method of claim 5 , wherein the cancer is lung cancer.
9. The method of claim 5 , wherein the cancer is pancreatic cancer.
10. The compound of claim 1 , wherein R 1a and R 1b are hydrogen.
11. The compound of claim 1 , wherein the compound has one of the following structures:
12. The compound of claim 11 , wherein R 4 is H.
13. The compound of claim 11 , wherein Y is N and Z is NCH 3 .
14. The compound of claim 11 , wherein R 1a is H or halogen.
15. The compound of claim 11 , wherein R 2 is —(C═O)R 8 , —C(═O)NR 10 R 11 or —S(═O) 2 R 8 .
16. The compound of claim 15 , wherein R 2 has one of the following structures:
17. A compound having one of the followings structures:
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof.
18. The compound of claim 1 , wherein R 1a is H or halogen.
19. The compound of claim 1 , wherein R 2 is SO 2 R 8 and R 8 is pyrrolidinyl.
20. The compound of claim 1 , wherein R 2 is SO 2 R 8 and R 8 is dimethylamino.
21. A compound having one of the following structures:
wherein R 1a is selected from hydrogen, halogen, OH, CN, SO 2 CH 3 , C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 polyhaloalkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 cyanoalky, and NH(C=0)R 7 ;
wherein R 7 is selected from hydrogen and C1-C6 alkyl;
wherein R 8 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and NR 10 R 11 ;
wherein R 10 is selected from hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl; and wherein R 11 , when present, is selected from hydrogen and C1-C6 alkyl; or R 10 and R 11 are covalently bonded and, together with the intermediate nitrogen, comprise an optionally substituted 3-7 membered heterocycloalkyl ring:
wherein R 3 is a halogen; and
wherein R 4 is selected from hydrogen, halogen, Ar 1 , C1-C6 alkyl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl,
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof.
22. The compound of claim 21 , wherein R 3 is chloro.
23. The compound of claim 21 , wherein R 3 is fluoro.
24. The compound of claim 21 , wherein R 4 is hydrogen.
25. The compound of claim 21 , wherein R 1a is H or halogen.
26. The compound of claim 2 , wherein R 8 is pyrrolidinyl or dimethylamino.
27. A compound having one of the following structures:
wherein L 2 is selected from CH 2 and NCH 3 , provided that L 2 is CH 2 when Y is N;
wherein Y is selected from CH or N;
wherein Z is selected from NR 6 and CH 2 ;
wherein R 6 is selected from hydrogen and CH 3 ;
wherein R 1a is selected from hydrogen, halogen, OH, CN, SO 2 CH 3 , C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 polyhaloalkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 cyanoalky, and NH(C═O)R 7 ;
wherein R 7 is selected from hydrogen and C1-C6 alkyl;
wherein R 2 has one of the following structures:
wherein R 3 is a halogen; and
wherein R 4 is selected from hydrogen, halogen, Ar 1 , C1-C6 alkyl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl;
wherein Ar 1 is either phenyl substituted with 0-3 substituents independently selected from cyano, C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino or is monocyclic heteroaryl substituted with 0-3 substituents independently selected from halo, cyano, C1-C6 alkyl, C1-C6 cyanoalkyl, C1-C6 haloalkyoxy, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl, C1-C6 cyanoalkyl, SO 2 R 12 , C1-C3 alkyl, C1-C3 alkylamine, and C1-C3 dialkylamino;
wherein R 12 is selected from C1-C6 alkyl and C3-C6 cycloalkyl;
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof.
28. The compound of claim 27 , wherein R 4 is hydrogen.
29. The compound of claim 27 , wherein R 3 is chloro.
30. The compound of claim 27 , wherein R 3 is fluoro.
31. The compound of claim 27 , wherein R 1a is H or halogen.